Leflunomide: a drug with a potential beyond rheumatology
about
Molecular targets in arthritis and recent trends in nanotherapyA High-Throughput Small Molecule Screen for C. elegans Linker Cell Death InhibitorsLeflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivoPrediction of drug indications based on chemical interactions and chemical similarities.Leflunomide Induces Pulmonary and Hepatic CYP1A Enzymes via Aryl Hydrocarbon Receptor.Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus.Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.New molecular targets for the treatment of sarcoidosis.Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Regulation of mammalian nucleotide metabolism and biosynthesisUtility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation.Tumor-related interleukins: old validated targets for new anti-cancer drug development.The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific.The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro.Immunoregulatory effects of 4-(4-chlorophenyl)-1-(5-amino-3-methylisoxazole-4-carbonyl)-thiosemicarbazide (06K) in non-immunized and SRBC-immunized mice.69-year-old woman with rheumatoid arthritis presents with shortness of breath and cough.Selective Cytotoxicity of Dihydroorotate Dehydrogenase Inhibitors to Human Cancer Cells Under Hypoxia and Nutrient-Deprived Conditions
P2860
Q26783466-2EE1F6B3-3BA0-43BF-9AC1-156339F97F49Q27320254-D38BF62E-79CE-4971-BEBB-3F395FA61992Q28535313-BC035BB9-AC29-4A29-992E-2511EAECA487Q35187910-5DA11ECF-134A-43C6-B7CA-B549E47D9032Q36316481-38EFC340-114B-487F-B4A0-5343DE6F4E52Q36686842-41D7BDFA-BE4A-4E19-B4C8-0B008FA39BFEQ37185408-F98C2F47-4C3B-4963-A374-D8B8091A6021Q37494750-DFD23C9A-0D9C-4AB8-A574-F08BE421A7B9Q37580399-D9E99354-CE3E-4131-B2C1-6C1BA9D40E0BQ38335072-12F41001-C0FF-4918-B4EB-899127795229Q38664637-88564AB6-1D6D-4221-A337-09DDB5407375Q40259831-5795F426-914A-4798-81B2-7968E162F2BFQ41716360-C31CEB6F-D96F-4EF7-9617-41872959F186Q42428805-F6CEF392-FD2B-4AFE-B9CA-58CC8C5E78CBQ42633382-566EB9EA-A32E-497A-8893-64B739C41E30Q50225755-32BC28E8-2CC3-4548-8AB8-2D2D47FFC2E1Q51671809-9F4BA3DD-2BF8-4259-89B7-0DDE94F0A149Q58764792-7D1E5066-8C01-4EEE-9B71-EFB120A4EA1E
P2860
Leflunomide: a drug with a potential beyond rheumatology
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Leflunomide: a drug with a potential beyond rheumatology
@ast
Leflunomide: a drug with a potential beyond rheumatology
@en
Leflunomide: a drug with a potential beyond rheumatology
@nl
type
label
Leflunomide: a drug with a potential beyond rheumatology
@ast
Leflunomide: a drug with a potential beyond rheumatology
@en
Leflunomide: a drug with a potential beyond rheumatology
@nl
prefLabel
Leflunomide: a drug with a potential beyond rheumatology
@ast
Leflunomide: a drug with a potential beyond rheumatology
@en
Leflunomide: a drug with a potential beyond rheumatology
@nl
P2860
P3181
P356
P1433
P1476
Leflunomide: a drug with a potential beyond rheumatology
@en
P2093
Sven Teschner
Volker Burst
P2860
P304
P3181
P356
10.2217/IMT.10.52
P407
P577
2010-09-01T00:00:00Z